Genmab A/S (GNMSF)
USD 203.33
(0.0%)
USD 203.33
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -14.09 Billion DKK | -51.65% |
| 2022 | -9.29 Billion DKK | -8.95% |
| 2021 | -8.53 Billion DKK | -22.92% |
| 2020 | -6.94 Billion DKK | -105.9% |
| 2019 | -3.37 Billion DKK | -532.57% |
| 2018 | -532.9 Million DKK | 60.45% |
| 2017 | -1.34 Billion DKK | -338.91% |
| 2016 | -307.02 Million DKK | 64.87% |
| 2015 | -873.86 Million DKK | -143.6% |
| 2014 | -358.73 Million DKK | -116.56% |
| 2013 | -165.65 Million DKK | -170.09% |
| 2012 | -61.33 Million DKK | -14.96% |
| 2011 | -53.35 Million DKK | -262.82% |
| 2010 | 32.76 Million DKK | 107.52% |
| 2009 | -435.79 Million DKK | -687.86% |
| 2008 | -55.31 Million DKK | 52.35% |
| 2007 | -116.08 Million DKK | 71.75% |
| 2006 | -410.86 Million DKK | -14.67% |
| 2005 | -358.31 Million DKK | 8.26% |
| 2004 | -390.56 Million DKK | -37.15% |
| 2003 | -284.77 Million DKK | -19.07% |
| 2002 | -239.17 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -13.66 Billion DKK | 3.1% |
| 2024 Q2 | -3.31 Billion DKK | 75.75% |
| 2023 Q2 | -10.07 Billion DKK | 12.11% |
| 2023 Q1 | -11.45 Billion DKK | -23.27% |
| 2023 Q4 | -14.09 Billion DKK | -4.58% |
| 2023 FY | -14.09 Billion DKK | -51.65% |
| 2023 Q3 | -13.48 Billion DKK | -33.85% |
| 2022 Q2 | -9.18 Billion DKK | -6.09% |
| 2022 Q3 | -9.74 Billion DKK | -6.16% |
| 2022 Q4 | -9.29 Billion DKK | 4.64% |
| 2022 Q1 | -8.65 Billion DKK | -1.44% |
| 2022 FY | -9.29 Billion DKK | -8.95% |
| 2021 Q1 | -7.51 Billion DKK | -8.26% |
| 2021 Q2 | -9.03 Billion DKK | -20.23% |
| 2021 Q3 | -8.29 Billion DKK | 8.21% |
| 2021 Q4 | -8.53 Billion DKK | -2.89% |
| 2021 FY | -8.53 Billion DKK | -22.92% |
| 2020 FY | -6.94 Billion DKK | -105.9% |
| 2020 Q1 | -5.36 Billion DKK | -59.27% |
| 2020 Q2 | -6.24 Billion DKK | -16.39% |
| 2020 Q3 | -8.55 Billion DKK | -36.9% |
| 2020 Q4 | -6.94 Billion DKK | 18.87% |
| 2019 Q3 | -4.45 Billion DKK | -1045.64% |
| 2019 Q4 | -3.37 Billion DKK | 24.32% |
| 2019 FY | -3.37 Billion DKK | -532.57% |
| 2019 Q2 | -388.81 Million DKK | 60.22% |
| 2019 Q1 | -977.38 Million DKK | -83.41% |
| 2018 Q2 | -1.08 Billion DKK | -13.63% |
| 2018 Q1 | -956.77 Million DKK | 29.0% |
| 2018 FY | -532.9 Million DKK | 60.45% |
| 2018 Q4 | -532.9 Million DKK | 40.53% |
| 2018 Q3 | -896.07 Million DKK | 17.58% |
| 2017 FY | -1.34 Billion DKK | -338.91% |
| 2017 Q3 | -1.08 Billion DKK | -5.31% |
| 2017 Q4 | -1.34 Billion DKK | -24.03% |
| 2017 Q2 | -1.03 Billion DKK | -34.97% |
| 2017 Q1 | -764.41 Million DKK | -148.98% |
| 2016 Q4 | -307.02 Million DKK | 61.46% |
| 2016 Q3 | -796.66 Million DKK | -24.15% |
| 2016 Q2 | -641.7 Million DKK | -1.08% |
| 2016 Q1 | -634.85 Million DKK | 27.35% |
| 2016 FY | -307.02 Million DKK | 64.87% |
| 2015 Q2 | -366.94 Million DKK | -11.79% |
| 2015 Q1 | -328.24 Million DKK | 8.5% |
| 2015 FY | -873.86 Million DKK | -143.6% |
| 2015 Q4 | -873.86 Million DKK | -49.61% |
| 2015 Q3 | -584.08 Million DKK | -59.18% |
| 2014 Q1 | -670.11 Million DKK | -304.54% |
| 2014 Q4 | -358.73 Million DKK | -32.19% |
| 2014 Q2 | -392.92 Million DKK | 41.36% |
| 2014 Q3 | -271.38 Million DKK | 30.93% |
| 2014 FY | -358.73 Million DKK | -116.56% |
| 2013 Q2 | -178.05 Million DKK | -46.19% |
| 2013 FY | -165.65 Million DKK | -170.09% |
| 2013 Q4 | -165.65 Million DKK | -572.28% |
| 2013 Q3 | -24.64 Million DKK | 86.16% |
| 2013 Q1 | -121.79 Million DKK | -98.59% |
| 2012 FY | -61.33 Million DKK | -14.96% |
| 2012 Q1 | -101.94 Million DKK | -91.08% |
| 2012 Q2 | -118.07 Million DKK | -15.82% |
| 2012 Q3 | -402.66 Million DKK | -241.03% |
| 2012 Q4 | -61.33 Million DKK | 84.77% |
| 2011 Q4 | -53.35 Million DKK | 64.81% |
| 2011 Q2 | -77.63 Million DKK | 8.65% |
| 2011 FY | -53.35 Million DKK | -262.82% |
| 2011 Q1 | -84.98 Million DKK | -359.36% |
| 2011 Q3 | -151.6 Million DKK | -95.29% |
| 2010 Q3 | -394.78 Million DKK | 4.62% |
| 2010 Q1 | -245.08 Million DKK | 43.76% |
| 2010 FY | 32.76 Million DKK | 107.52% |
| 2010 Q2 | -413.89 Million DKK | -68.88% |
| 2010 Q4 | 32.76 Million DKK | 108.3% |
| 2009 FY | -435.79 Million DKK | -687.86% |
| 2009 Q4 | -435.79 Million DKK | 0.0% |
| 2008 FY | -55.31 Million DKK | 52.35% |
| 2007 FY | -116.08 Million DKK | 71.75% |
| 2006 FY | -410.86 Million DKK | -14.67% |
| 2005 FY | -358.31 Million DKK | 8.26% |
| 2004 FY | -390.56 Million DKK | -37.15% |
| 2003 FY | -284.77 Million DKK | -19.07% |
| 2002 FY | -239.17 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 89530.946% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 342424.377% |
| SQZ Biotechnologies Company | -36.23 Million USD | -38801.153% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 33042.304% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -223501.338% |
| Mesoblast Limited | 55.85 Million USD | 25337.093% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1520506.909% |
| Genus plc | 190.6 Million USD | 7496.118% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 630603.544% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1161409.775% |
| Marizyme, Inc. | 18.56 Million USD | 76016.732% |
| ContraFect Corporation | -6.02 Million USD | -233836.276% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 2073188.235% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 10470320.367% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1220166.313% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 628803.618% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 256320.765% |
| MultiCell Technologies, Inc. | 90.04 USD | 15656375044.469% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1920529.774% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 108990.777% |
| EV Biologics, Inc. | 1.36 Million USD | 1030604.302% |
| Q BioMed Inc. | 4.06 Million USD | 347316.065% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 46237.985% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 2265173.173% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1399006.041% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1981680.035% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 12938.33% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 110176.14% |
| Skye Bioscience, Inc. | -5.72 Million USD | -246291.217% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1638826.822% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 10083502.478% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 249676.426% |
| IMV Inc. | 7.67 Million USD | 183881.519% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 70956963.14% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 640296.26% |
| GB Sciences, Inc. | 1.74 Million USD | 806880.228% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -7670150.506% |
| HST Global, Inc. | 96.79 Thousand USD | 14564169.716% |
| CSL Limited | 10.52 Billion USD | 233.926% |
| Halberd Corporation | 144.72 Thousand USD | 9740911.631% |
| Enzolytics Inc. | 981.65 Thousand USD | 1436142.769% |
| Resverlogix Corp. | 6.45 Million USD | 218624.26% |
| Affymax, Inc. | -5.59 Million USD | -251767.072% |
| SYBLEU INC | 473.71 Thousand USD | 2975946.186% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -2094273.85% |
| argenx SE | -2.02 Billion USD | -594.829% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 32556.14% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -29885.961% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 520550.489% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -159369.913% |
| AVAX Technologies, Inc. | -5.9 Million USD | -238702.4% |
| Zenith Capital Corp. | 10.06 Thousand USD | 140073629.412% |
| Genscript Biotech Corporation | -1.06 Billion USD | -1228.233% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 7033408.055% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 590913.04% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 8569236.035% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 23383.219% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 705164.34% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -548414.571% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 3919090.298% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 69625.547% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -76956991.386% |
| BioStem Technologies, Inc. | 4.47 Million USD | 315327.31% |
| ONE Bio Corp. | 9.04 Million USD | 156039.662% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 7004681.275% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -1076106770.229% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 6836102.851% |
| Agentix Corp. | 37.63 Thousand USD | 37461235.766% |
| LadRx Corporation | -2.03 Million USD | -692127.576% |
| Cell Source, Inc. | 9.23 Million USD | 152797.62% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -69075752.607% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2219516.311% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2219516.311% |
| NovAccess Global Inc. | 2.17 Million USD | 647207.023% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 199464.387% |
| Itoco Inc. | 228.3 Thousand USD | 6174734.809% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 10366379.626% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 284485.717% |
| Kadimastem Ltd | -253.1 Thousand USD | -5569591.271% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 3508134.112% |
| CytoDyn Inc. | 20.26 Million USD | 69673.586% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -2178825247.759% |
| Mobile Lads Corp. | 484.23 Thousand USD | 2911307.851% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -152098334.024% |
| Qrons Inc. | 351.42 Thousand USD | 4011459.4% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 183035.328% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -5647284.024% |
| Rebus Holdings, Inc. | 305 Thousand USD | 4622067.213% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 316387.422% |
| International Stem Cell Corporation | 2.59 Million USD | 544385.714% |
| Bioxytran, Inc. | 1.89 Million USD | 742471.692% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 22586740.604% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 646484.52% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 410612.522% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 164919.362% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1824701.641% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -1127660.0% |
| Neutra Corp. | 52.18 Thousand USD | 27012574.371% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -566272.037% |
| PureTech Health plc | -167.19 Million USD | -8331.371% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -5755939.002% |
| IXICO plc | -4.44 Million USD | -317072.327% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 106741.955% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 25800.534% |
| CSL Limited | 10.52 Billion USD | 233.926% |
| Cellectis S.A. | -43.81 Million USD | -32071.069% |